A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies.
Chen XC, Yu B, Dong JC, Gu YX, Chen L, Wu QZ, Hou NP, Liu JX, Xu JT, Jin RX, Jin GQ, Yang XD, Cao YW, Tan JJ, Zhu B, Shen JC, Xu Z, Varticovski L, Wang XW.
Chen XC, et al. Among authors: gu yx.
Anticancer Res. 2007 May-Jun;27(3B):1593-600.
Anticancer Res. 2007.
PMID: 17595781
Free article.
Clinical Trial.